{"id":"NCT03746522","sponsor":"Rhythm Pharmaceuticals, Inc.","briefTitle":"Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity","officialTitle":"A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-23","primaryCompletion":"2020-11-16","completion":"2021-03-08","firstPosted":"2018-11-19","resultsPosted":"2023-12-01","lastUpdate":"2023-12-01"},"enrollment":52,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bardet Biedl Syndrome (BBS)","Alström Syndrome (AS)"],"interventions":[{"type":"DRUG","name":"Setmelanotide","otherNames":["SET","RM-493"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Setmelanotide (Double-Blind)","type":"EXPERIMENTAL"},{"label":"Placebo (Double-Blind)","type":"PLACEBO_COMPARATOR"},{"label":"Setmelanotide (Open-label)","type":"EXPERIMENTAL"}],"summary":"This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl syndrome (BBS) or Alström syndrome (AS). The study's primary efficacy endpoint is to evaluate the proportion of participants (≥ 12 years of age at baseline) who lose ≥ 10% of their baseline body weight following approximately (\\~) 52 weeks of treatment with setmelanotide compared to a historical control rate.","primaryOutcome":{"measure":"Percentage of Participants (≥12 Years of Age at Baseline) Who Reached ≥10% Weight Loss Threshold After 1 Year (Period 2): Pivotal Cohort","timeFrame":"52 weeks","effectByArm":[{"arm":"Pivotal Cohort","deltaMin":32.3,"sd":null}],"pValues":[{"comp":"OG000","p":"0.0006"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":12,"countries":["United States","Canada","France","Puerto Rico","Spain","United Kingdom"]},"refs":{"pmids":["36961653","36647077","36356613","34013094"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":27},"commonTop":["Skin hyperpigmentation","Injection site erythema","Injection site pruritus","Nausea","Injection site bruising"]}}